Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Amgen Loses Appeal Over Antibody Patent in Sanofi Fight (1)

Feb. 11, 2021, 4:43 PM

Amgen Inc. lost an appeals court bid to revive two patents for its Repatha cholesterol drug, a victory for Sanofi and Regeneron Pharmaceuticals Inc. in their long-running fight over rival medicine Praluent.

A trial court was correct to invalidate the patents, the U.S. Court of Appeals for the Federal Circuit ruled Thursday in a closely watched case over how or whether patents can be granted for a new group of antibodies.

The two Amgen patents, which were due to expire in August 2028, are related to antibodies called PCSK9 inhibitors, which help patients with ultra-high bad, or LDL, cholesterol who ...